Spotlight on Hematology

Credits: 1.00 CME / CNE / CPE
Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL
Matthew Davids, MD, MMSc
Rush University Medical Center

Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 24, 2021
Expires:September 23, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
  • Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
  • Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
  • Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 24, 2021
Expires:September 23, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
  • Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
  • Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
  • Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Hematology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
β-Thalassemia in 2021: Overview of the Disease and its Management, Including Novel Therapies in Development

β-Thalassemia in 2021: Overview of the Disease and its Management, Including Novel Therapies in Development

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 14, 2021
Expires: October 13, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with β-Thalassemia.

Learning Objectives

After completing this program, participants should be able to:

  • Provide an overview of our understanding of the disease and its management in 2021
  • Discuss safety and efficacy of different iron chelators used for treatment of iron overload in patients with β-Thalassemia
  • Identify the patients who are candidates for stem cell transplant
  • Discuss the safety, efficacy, and medical need of novel therapeutic approaches like use of erythroid maturation agents to reduce transfusion burden in patients with β-Thalassemia
  • Assess the safety and efficacy data on emerging gene therapy strategies in various clinical trials
  • Implement models to enhance patient education and empower young patients to adequately manage their illness and transition to adult care setting

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of β-Thalassemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In spite of the recent treatment advances, clinicians still face significant challenges when it comes to providing comprehensive care to β-Thalassemia patients. Often clinicians may not be fully aware of the updated treatment recommendations for RBC transfusion, iron chelation, and safety and efficacy of iron chelating agents.

With FDA approval of agents that can reduce RBC transfusion burden in transfusion dependent β-Thalassemia patients, it is important that clinicians stay abreast with these treatment advances.

Faculty

Sujit Sheth, MD
Chief, Division of Pediatric Hematology/Oncology
Weill Cornell Medical Center
New York, NY


Shivi Jain, MD
Assistant Professor of Medicine
Division of Hematology/Oncology/Cell Therapy
Rush University Medical Center
Chicago, IL

Conflict of Interest Policy/Disclosure Statement

Dr. Sheth’s Disclosures:

  • Consultant:
    • Bluebird bio
    • Celgene/Bristol Myers Squibb/Acceleron
    • Agios
    • Chiesi
  • Steering Committee:
    • CRISPR/Vertex CTX001
  • Will discuss therapeutics not yet FDA approved – results from clinical trials

Dr. Jain’s Disclosures:

  • Advisory Board Panel:
    • Dova
    • Sanofi
    • Argenex
  • Speaker’s Bureau:
    • Novartis, GBT
  • CME Courses:
    • CME course speaker: ITP: Clinical Viewpoints
    • CME course director: Beta Thalassemia: Plexus communication
  • Board Member:
    • Sickle cell disease association of Illinois

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour(s) requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS and Chiesi Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 14, 2021
Expires: October 13, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with β-Thalassemia.

Learning Objectives

After completing this program, participants should be able to:

  • Provide an overview of our understanding of the disease and its management in 2021
  • Discuss safety and efficacy of different iron chelators used for treatment of iron overload in patients with β-Thalassemia
  • Identify the patients who are candidates for stem cell transplant
  • Discuss the safety, efficacy, and medical need of novel therapeutic approaches like use of erythroid maturation agents to reduce transfusion burden in patients with β-Thalassemia
  • Assess the safety and efficacy data on emerging gene therapy strategies in various clinical trials
  • Implement models to enhance patient education and empower young patients to adequately manage their illness and transition to adult care setting

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of β-Thalassemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In spite of the recent treatment advances, clinicians still face significant challenges when it comes to providing comprehensive care to β-Thalassemia patients. Often clinicians may not be fully aware of the updated treatment recommendations for RBC transfusion, iron chelation, and safety and efficacy of iron chelating agents.

With FDA approval of agents that can reduce RBC transfusion burden in transfusion dependent β-Thalassemia patients, it is important that clinicians stay abreast with these treatment advances.

Faculty

Sujit Sheth, MD
Chief, Division of Pediatric Hematology/Oncology
Weill Cornell Medical Center
New York, NY


Shivi Jain, MD
Assistant Professor of Medicine
Division of Hematology/Oncology/Cell Therapy
Rush University Medical Center
Chicago, IL

Conflict of Interest Policy/Disclosure Statement

Dr. Sheth’s Disclosures:

  • Consultant:
    • Bluebird bio
    • Celgene/Bristol Myers Squibb/Acceleron
    • Agios
    • Chiesi
  • Steering Committee:
    • CRISPR/Vertex CTX001
  • Will discuss therapeutics not yet FDA approved – results from clinical trials

Dr. Jain’s Disclosures:

  • Advisory Board Panel:
    • Dova
    • Sanofi
    • Argenex
  • Speaker’s Bureau:
    • Novartis, GBT
  • CME Courses:
    • CME course speaker: ITP: Clinical Viewpoints
    • CME course director: Beta Thalassemia: Plexus communication
  • Board Member:
    • Sickle cell disease association of Illinois

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour(s) requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS and Chiesi Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME
University of Nebraska Medical Center
Expert Insights: Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas

Expert Insights: Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 24, 2021
Expires: September 24, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
  • Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
  • Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma

Activity Description

Major advances in the diagnosis and treatment of aggressive lymphoma have occurred in the past few years. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with lymphoma need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity provides a discussion between two lymphoma experts as they explore challenging, real-world case scenarios in DLBCL, MCL, and rare aggressive lymphoma subtypes.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with aggressive lymphoma subtypes (including diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], and others), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Ranjana Advani, MD
CONSULTANT: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi

RESEARCH FUNDING: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/Genentech; Seattle Genetics; Takeda/Millennium

ADVISORY BOARD: Roche/Genentech

HONORARIUM: Roche/Genentech

Matthew Lunning, DO, FACP
CONSULTANT: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem

RESEARCH GRANT SUPPORT: Bristol Myers Squibb; Curis

ADVISORY BOARD: Celgene

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing; Dru Dace, PhD

Faculty

Moderator
Matthew Lunning, DO, FACP
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska


Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California

Continuing Education

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Incyte Corporation, MorphoSys, and TG Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 24, 2021
Expires: September 24, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
  • Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
  • Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma

Activity Description

Major advances in the diagnosis and treatment of aggressive lymphoma have occurred in the past few years. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with lymphoma need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity provides a discussion between two lymphoma experts as they explore challenging, real-world case scenarios in DLBCL, MCL, and rare aggressive lymphoma subtypes.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with aggressive lymphoma subtypes (including diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], and others), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Ranjana Advani, MD
CONSULTANT: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi

RESEARCH FUNDING: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/Genentech; Seattle Genetics; Takeda/Millennium

ADVISORY BOARD: Roche/Genentech

HONORARIUM: Roche/Genentech

Matthew Lunning, DO, FACP
CONSULTANT: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem

RESEARCH GRANT SUPPORT: Bristol Myers Squibb; Curis

ADVISORY BOARD: Celgene

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing; Dru Dace, PhD

Faculty

Moderator
Matthew Lunning, DO, FACP
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska


Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California

Continuing Education

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Incyte Corporation, MorphoSys, and TG Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL

Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 24, 2021
Expires:September 23, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
  • Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
  • Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
  • Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 24, 2021
Expires:September 23, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
  • Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
  • Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
  • Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME
Postgraduate Institute for Medicine
Expert Insights: Practical Aspects of Incorporating CAR T-Cell Therapy into Your Practice

Expert Insights: Practical Aspects of Incorporating CAR T-Cell Therapy into Your Practice

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 9, 2021
Expires: September 9, 2022
15 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate CAR T-cell therapy into clinical practice, and identify appropriate patients
  • Develop strategies to mitigate treatment-related adverse events that may occur during treatment with CAR T-cell therapy
  • Discuss the emerging results of clinical trials that are investigating CAR T-cell therapies in lymphoma and myeloma
  • Optimize the referral process and multidisciplinary care for patients who qualify for CAR T-cell therapy

Faculty Disclosures

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consultant Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis


Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma and Myeloma
Director, Lymphoma Outcomes Database
Section Chief, New Drug Development
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Consultant Fees: Celgene, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Takeda, TG Therapeutics
Contracted Research: Celgene, Epizyme, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Merck, Takeda

Planning Committee
The PIM planners and managers have nothing to disclose. The Bio Ascend LLC planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Legend Biotech.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 9, 2021
Expires: September 9, 2022
15 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate CAR T-cell therapy into clinical practice, and identify appropriate patients
  • Develop strategies to mitigate treatment-related adverse events that may occur during treatment with CAR T-cell therapy
  • Discuss the emerging results of clinical trials that are investigating CAR T-cell therapies in lymphoma and myeloma
  • Optimize the referral process and multidisciplinary care for patients who qualify for CAR T-cell therapy

Faculty Disclosures

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consultant Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis


Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma and Myeloma
Director, Lymphoma Outcomes Database
Section Chief, New Drug Development
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Consultant Fees: Celgene, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Takeda, TG Therapeutics
Contracted Research: Celgene, Epizyme, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Merck, Takeda

Planning Committee
The PIM planners and managers have nothing to disclose. The Bio Ascend LLC planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Legend Biotech.

Contact Information for Questions About the Activity

info@bioascend.com

0.75 CME
University of Nebraska Medical Center
Podium to Practice: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data

Podium to Practice: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 30, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Activity Description

The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, many clinical questions arise, including ideal sequencing of agents, role of MRD, management of adverse events, and incorporating emerging data of investigational agents. This activity will provide expert interpretation of recently presented data regarding currently available and emerging therapies for the treatment of patients with relapsed or refractory multiple myeloma.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Moderator

Cristina Gasparetto, MD
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Faculty

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Cristina Gasparetto, MD (Moderator)
Consulting Fees: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Contracted Research: GlaxoSmithKline

Maria-Victoria Mateos, MD, PhD
Honorarium (Lectures): Adaptive Biotechnologies, Amgen, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi, Takeda
Honorarium (Advisory Boards): Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Pfizer Inc., Regeneron, Roche, Sanofi, SeaGen, Takeda

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

Accreditation Statement

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 30, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Activity Description

The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, many clinical questions arise, including ideal sequencing of agents, role of MRD, management of adverse events, and incorporating emerging data of investigational agents. This activity will provide expert interpretation of recently presented data regarding currently available and emerging therapies for the treatment of patients with relapsed or refractory multiple myeloma.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Moderator

Cristina Gasparetto, MD
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Faculty

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Cristina Gasparetto, MD (Moderator)
Consulting Fees: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Contracted Research: GlaxoSmithKline

Maria-Victoria Mateos, MD, PhD
Honorarium (Lectures): Adaptive Biotechnologies, Amgen, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi, Takeda
Honorarium (Advisory Boards): Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Pfizer Inc., Regeneron, Roche, Sanofi, SeaGen, Takeda

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

Accreditation Statement

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

0.50 CME
University of Nebraska Medical Center
On Topic Virtual Roundtable: Multidisciplinary Perspectives on the Changing Care of Relapsed/Refractory Multiple Myeloma

On Topic Virtual Roundtable: Multidisciplinary Perspectives on the Changing Care of Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 24, 2021
Expires: August 24, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss factors that impact the selection of therapy for patients at first relapse, including certain patient- and disease-related factors, as well as previous agents received
  • Assess treatment strategies for patients with MM that are in their 2nd relapse and beyond, including the incorporation of recently approved agents and the potential for clinical trial enrollment exploring novel regimens
  • Develop strategies to optimize patient related outcomes, including mitigating adverse events, improving quality of life, and recognizing the role of the patient voice in selecting therapeutic approaches

Activity Description

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity aims to provide community-based clinicians with clinical recommendations to address treatment options for patients with R/R MM via myeloma experts.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Agenda

Setting the Stage for Success

The Changing Therapeutic Landscape for Relapsed/Refractory Multiple Myeloma

Practical Approaches to Patient-Centered Care

Key Takeaways

Moderator

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Faculty

Caitlin Costello, MD
Associate Clinical Professor of Medicine
UC San Diego Health
UCSD/Sharp Healthcare Transplant Program
Blood & Marrow Transplant Services
Moores Cancer Center
La Jolla, California


Sandra Kurtin, PhD, ANP-C, AOCN
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Patient Advocate

Tom Tucker
Co-Leader, Multiple Myeloma San Diego Support Group
15-year Multiple Myeloma Survivor

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty and Patient Advocate
Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator)
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Caitlin Costello, MD
Consultant/Research Funding: Bristol Myers Squibb Company, Janssen, Takeda

Sandra Kurtin, PhD, ANP-C, AOCN
Consultant: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Sanofi, Incyte Corporation

Tom Tucker
No relevant financial relationships to disclose

Planning Committee
The following planning committee members have nothing to disclose except for the following:

Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and Conflict of Interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Karyopharm, Sanofi, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 24, 2021
Expires: August 24, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss factors that impact the selection of therapy for patients at first relapse, including certain patient- and disease-related factors, as well as previous agents received
  • Assess treatment strategies for patients with MM that are in their 2nd relapse and beyond, including the incorporation of recently approved agents and the potential for clinical trial enrollment exploring novel regimens
  • Develop strategies to optimize patient related outcomes, including mitigating adverse events, improving quality of life, and recognizing the role of the patient voice in selecting therapeutic approaches

Activity Description

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity aims to provide community-based clinicians with clinical recommendations to address treatment options for patients with R/R MM via myeloma experts.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Agenda

Setting the Stage for Success

The Changing Therapeutic Landscape for Relapsed/Refractory Multiple Myeloma

Practical Approaches to Patient-Centered Care

Key Takeaways

Moderator

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Faculty

Caitlin Costello, MD
Associate Clinical Professor of Medicine
UC San Diego Health
UCSD/Sharp Healthcare Transplant Program
Blood & Marrow Transplant Services
Moores Cancer Center
La Jolla, California


Sandra Kurtin, PhD, ANP-C, AOCN
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Patient Advocate

Tom Tucker
Co-Leader, Multiple Myeloma San Diego Support Group
15-year Multiple Myeloma Survivor

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty and Patient Advocate
Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator)
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Caitlin Costello, MD
Consultant/Research Funding: Bristol Myers Squibb Company, Janssen, Takeda

Sandra Kurtin, PhD, ANP-C, AOCN
Consultant: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Sanofi, Incyte Corporation

Tom Tucker
No relevant financial relationships to disclose

Planning Committee
The following planning committee members have nothing to disclose except for the following:

Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and Conflict of Interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Karyopharm, Sanofi, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

0.50 CME
Postgraduate Institute for Medicine
Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 5, 2021
Expires: August 5, 2022
30 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 5, 2021
Expires: August 5, 2022
30 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Optimizing the Care of Mantle Cell Lymphoma: Translating the Latest Advances into Clinical Practice

Optimizing the Care of Mantle Cell Lymphoma: Translating the Latest Advances into Clinical Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 26, 2021
Expires: July 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with mantle cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with mantle cell lymphoma and identify those most likely to benefit from treatment using prognostic indicators
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with mantle cell lymphoma
  3. Formulate best-practice treatment strategies for patients with mantle cell lymphoma, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of mantle cell lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The therapeutic field for MCL is rapidly expanding with an increasing number of targeted therapies, immunotherapies, and novel combination regimens. It is difficult for community oncologists, who see a limited number of patients with MCL, to keep pace with rapidly evolving treatment paradigms, as well as distinguish among these new and emerging strategies in order to best incorporate them into clinical practice.

As treatment for MCL evolves beyond conventional chemoimmunotherapies and ACST, clinicians will require familiarity with the unique safety considerations associated with targeted agents and immunotherapies in order to optimize clinical outcomes.

In addition, diagnosis of MCL presents a clinical challenge given that a community oncologist may only see a patient with MCL once or twice a year, and those patients may have radically different presentations and clinical behaviors. Clinicians are challenged to incorporate available diagnostic criteria, risk stratification, and prognostic indicators that can be used to personalize therapy decisions for this relatively rare hematologic malignancy.

Faculty

Jonathon B. Cohen, MD, MS
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Medical Director, Infusion Services
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has consulted for:
Loxo, Adaptive, Adicet, Cellectar, Beigene, AstraZeneca, Janssen, Pharmacyclics, Kite

Dr. Cohen has research grants from
Genentech, Novartis, BMS/Celgene, LOXO, LAM, BeiGene, Takeda, BioInvent, AstraZeneca

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc. and Kite Pharma, Inc..

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 26, 2021
Expires: July 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with mantle cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with mantle cell lymphoma and identify those most likely to benefit from treatment using prognostic indicators
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with mantle cell lymphoma
  3. Formulate best-practice treatment strategies for patients with mantle cell lymphoma, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of mantle cell lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The therapeutic field for MCL is rapidly expanding with an increasing number of targeted therapies, immunotherapies, and novel combination regimens. It is difficult for community oncologists, who see a limited number of patients with MCL, to keep pace with rapidly evolving treatment paradigms, as well as distinguish among these new and emerging strategies in order to best incorporate them into clinical practice.

As treatment for MCL evolves beyond conventional chemoimmunotherapies and ACST, clinicians will require familiarity with the unique safety considerations associated with targeted agents and immunotherapies in order to optimize clinical outcomes.

In addition, diagnosis of MCL presents a clinical challenge given that a community oncologist may only see a patient with MCL once or twice a year, and those patients may have radically different presentations and clinical behaviors. Clinicians are challenged to incorporate available diagnostic criteria, risk stratification, and prognostic indicators that can be used to personalize therapy decisions for this relatively rare hematologic malignancy.

Faculty

Jonathon B. Cohen, MD, MS
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Medical Director, Infusion Services
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has consulted for:
Loxo, Adaptive, Adicet, Cellectar, Beigene, AstraZeneca, Janssen, Pharmacyclics, Kite

Dr. Cohen has research grants from
Genentech, Novartis, BMS/Celgene, LOXO, LAM, BeiGene, Takeda, BioInvent, AstraZeneca

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc. and Kite Pharma, Inc..

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME
The France Foundation
Conquer the Clot: Addressing VTE in Your Patients With Cancer

Conquer the Clot: Addressing VTE in Your Patients With Cancer

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 7, 2021
Expires: July 6, 2022
60 minutes to complete

Provided By

Target Audience

This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other health care professionals who are involved in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.

Learning Objectives

  • Identify appropriate patients for primary VTE prophylaxis through risk stratification assessments
  • Establish a plan for prevention of VTE in patients at elevated risk
  • Select appropriate therapy to treat VTE in patients with cancer, and select appropriate duration of treatment
  • Discuss with patients the risk and prevention of VTE

Activity Description

This 60-minute session provides education to the oncology team to support guideline-recommended care of patients with cancer, specifically related to: 1) appropriate VTE risk assessment and prophylaxis; 2) individualized VTE treatment; and 3) effective patient communication strategies related to VTE risk, prevention, and treatment. Throughout the session, the content is anchored in patient-care videos to engage the learner.

Statement of Educational Need

The prevention and treatment of cancer-associated thrombosis remains one of the most challenging areas of clinical medicine due to the intersection of cancer care and thrombosis management. Despite recent advances in patient risk stratification, prevention efforts, and treatment strategies, which have provided clinicians and patients with unprecedented management choices, individualized patient-centered management is needed to deliver optimal care.

Agenda

Know the Risk: Are Your Patients Protected? - Michael B. Streiff, MD, FACP
Critical Care: Preventing Cancer Associated Thrombosis in Your Patients - Alok A. Khorana, MD, FACP, FASCO
Conquer the Clot: Treating VTE in Your Patients With Cancer - Tzu-Fei Wang, MD, MPH

Faculty

Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Chair in Oncology Research
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Taussig Cancer Institute and Case Comprehensive Cancer Center
Cleveland, Ohio


Michael B. Streiff, MD, FACP
Professor of Medicine and Pathology
Medical Director, Johns Hopkins Anticoagulation Service
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chairman, NCCN Guidelines for Venous Thromboembolic Disease
Baltimore, Maryland


Tzu-Fei Wang, MD, MPH
Associate Professor, Division of Hematology, Department of Medicine
University of Ottawa at The Ottawa Hospital
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Canada

Faculty Disclosures

The faculty listed below report that they have relevant financial relationships to disclose:

  • Alok A. Khorana, MD, FACP, FASCO, serves as a consultant for Anthos, Bayer, BMS, Halozyme, Janssen, and Sanofi.
  • Michael B. Streiff, MD, FACP, serves as a consultant for Bayer, Bristol-Myers Squibb, Coagulo, Dispersol, Janssen, and Pfizer. He also receives research support from AHRQ, Janssen, NIH/NHLBI, Novo Nordisk, PCORI, Sanofi, and Tremeau.
  • Tzu-Fei Wang, MD, MPH, serves as a consultant for Servier. She also receives contract research support from Leo Pharma.

Accreditation Statement

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of at least 75% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Statement of Commercial Support

This activity is supported by an educational grant from the BMS/Pfizer Alliance.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 7, 2021
Expires: July 6, 2022
60 minutes to complete

Provided By

Target Audience

This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other health care professionals who are involved in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.

Learning Objectives

  • Identify appropriate patients for primary VTE prophylaxis through risk stratification assessments
  • Establish a plan for prevention of VTE in patients at elevated risk
  • Select appropriate therapy to treat VTE in patients with cancer, and select appropriate duration of treatment
  • Discuss with patients the risk and prevention of VTE

Activity Description

This 60-minute session provides education to the oncology team to support guideline-recommended care of patients with cancer, specifically related to: 1) appropriate VTE risk assessment and prophylaxis; 2) individualized VTE treatment; and 3) effective patient communication strategies related to VTE risk, prevention, and treatment. Throughout the session, the content is anchored in patient-care videos to engage the learner.

Statement of Educational Need

The prevention and treatment of cancer-associated thrombosis remains one of the most challenging areas of clinical medicine due to the intersection of cancer care and thrombosis management. Despite recent advances in patient risk stratification, prevention efforts, and treatment strategies, which have provided clinicians and patients with unprecedented management choices, individualized patient-centered management is needed to deliver optimal care.

Agenda

Know the Risk: Are Your Patients Protected? - Michael B. Streiff, MD, FACP
Critical Care: Preventing Cancer Associated Thrombosis in Your Patients - Alok A. Khorana, MD, FACP, FASCO
Conquer the Clot: Treating VTE in Your Patients With Cancer - Tzu-Fei Wang, MD, MPH

Faculty

Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Chair in Oncology Research
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Taussig Cancer Institute and Case Comprehensive Cancer Center
Cleveland, Ohio


Michael B. Streiff, MD, FACP
Professor of Medicine and Pathology
Medical Director, Johns Hopkins Anticoagulation Service
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chairman, NCCN Guidelines for Venous Thromboembolic Disease
Baltimore, Maryland


Tzu-Fei Wang, MD, MPH
Associate Professor, Division of Hematology, Department of Medicine
University of Ottawa at The Ottawa Hospital
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Canada

Faculty Disclosures

The faculty listed below report that they have relevant financial relationships to disclose:

  • Alok A. Khorana, MD, FACP, FASCO, serves as a consultant for Anthos, Bayer, BMS, Halozyme, Janssen, and Sanofi.
  • Michael B. Streiff, MD, FACP, serves as a consultant for Bayer, Bristol-Myers Squibb, Coagulo, Dispersol, Janssen, and Pfizer. He also receives research support from AHRQ, Janssen, NIH/NHLBI, Novo Nordisk, PCORI, Sanofi, and Tremeau.
  • Tzu-Fei Wang, MD, MPH, serves as a consultant for Servier. She also receives contract research support from Leo Pharma.

Accreditation Statement

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of at least 75% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Statement of Commercial Support

This activity is supported by an educational grant from the BMS/Pfizer Alliance.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.75 CME / MOC / CNE
RMEI Medical Education, LLC
Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Pages